Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in refractory primary bone tumors (pediatric/young adult)
2021-005339-22Phase 2Active
- Sponsor
- Institute of Mother and Child
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of regorafenib in Primary Bone Tumor, Ewing sarcoma and cancer, sponsored by Institute of Mother and Child. Primary endpoint: Event-Free Survival (EFS). Started Dec 2021; status: active.
02
Drugs
regorafenib
03
Conditions
Primary Bone TumorEwing sarcomacancer
Beyond the preview
Go deeper on 2021-005339-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005339-22.